|
09/05/23
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep. 5, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference, Monday, September 11
|
|
|
08/16/23
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Aug. 16, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel).
|
|
|
08/08/23
|
- Continued strong commercial launch for ZYNTEGLO ® and SKYSONA ® ; 16 patient starts across both programs to date – - Biologics License Application (BLA) for lovo-cel for sickle cell disease accepted for FDA priority review; PDUFA goal date December 20, 2023 - - Ended quarter with $291M in cash,
|
|
|
07/25/23
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jul. 25, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) today announced it will hold a conference call to discuss second quarter 2023 financial results and provide a commercial update on Tuesday, August 8 at 8:00 a.m. ET .
|
|
|
06/21/23
|
BLA submission based on data from the largest and most mature clinical development program for any gene therapy in sickle cell disease PDUFA date set for December 20, 2023 SOMERVILLE, Mass. --(BUSINESS WIRE)--Jun. 21, 2023-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S.
|
|
|
05/09/23
|
- Biologics License Application (BLA) for lovo-cel for sickle cell disease submitted to FDA - - First commercial infusions completed for both ZYNTEGLO ® and SKYSONA ® - - Ended quarter with $ 364M in cash, cash equivalents, marketable securities and restricted cash – SOMERVILLE, Mass.
|
|
|
04/27/23
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. 27, 2023-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Company’s first quarter financial results, including commercial, regulatory and operational updates, will be released pre-market on Tuesday, May 9 .
|
|
|
04/24/23
|
BLA submission based on data from the largest and most mature clinical development program for any gene therapy in sickle cell disease SOMERVILLE, Mass. --(BUSINESS WIRE)--Apr. 24, 2023-- bluebird bio, Inc . (Nasdaq: BLUE) today announced the submission of its Biologics License Application (BLA) to
|
|
|
03/29/23
|
- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 7 patient starts (cell collections) across both programs to date - - Update on Biologics License Application (BLA) submission for lovo-cel for sickle cell disease (SCD) - - Management to host conference call today, March 29, 2023 at
|
|
|
01/18/23
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 18, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and
|
|
|
01/18/23
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 18, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an
|
|
|
01/09/23
|
- First commercially treated ZYNTEGLO patient apheresed in Q4 2022; first revenue anticipated in Q1 2023 - - lovo-cel BLA submission on track for Q1 2023; vector and drug product analytical comparability studies complete - - Company enters 2023 with c ash runway into Q1 2024 - SOMERVILLE, Mass.
|
|
|
01/06/23
|
– Non-dilutive capital further strengthens Company’s financial position – SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 6, 2023-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric
|
|
|
01/05/23
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 5, 2023-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that Andrew Obenshain , chief executive officer, bluebird bio, will present a corporate update at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 , at 7:30AM PT .
|
|
|
01/03/23
|
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 3, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio , JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing,
|
|